Innovative treatment programs against cancer
- 1 January 1999
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 57 (1) , 9-17
- https://doi.org/10.1016/s0006-2952(98)00224-x
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- A20 Inhibits NF-κB Activation Independently of Binding to 14-3-3 ProteinsBiochemical and Biophysical Research Communications, 1997
- Transforming growth factor-β1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell lineInternational Journal of Cancer, 1997
- I kappa B epsilon, a novel member of the Ikappa B family, controls RelA and cRel NF-kappa B activityThe EMBO Journal, 1997
- TGF-β1 Triggers Oxidative Modifications and Enhances Apoptosis in Hit Cells Through Accumulation of Reactive Oxygen Species by Suppression of Catalase and Glutathione PeroxidaseFree Radical Biology & Medicine, 1997
- Proteasome-Dependent Regulation of p21WAF1/CIP1ExpressionBiochemical and Biophysical Research Communications, 1996
- Proteolytic processing of nuclear factor κB by calpain in vitroFEBS Letters, 1996
- Selective Inhibition of p70 S6 Kinase Activation by Phosphatidylinositol 3‐Kinase InhibitorsEuropean Journal of Biochemistry, 1995
- Gliotoxin Stimulates Ca2+ Release from Intact Rat Liver MitochondriaBiochemistry, 1994
- Simultaneous Activation of p90rsk and p70s6k S6 Kinases by Growth Hormone in 3T3-F442A PreadipocytesBiochemical and Biophysical Research Communications, 1993
- Apoptosis induced in macrophages and T blasts by the mycotoxin sporidesmin and protection by Zn2+ saltsInternational Journal of Immunopharmacology, 1990